Biocomposites’ STIMULAN Earns CE Mark

Biocomposites, an international medical devices company that engineers, manufactures, and markets products for use in infection management in bone and soft tissue, announced its STIMULAN products have gained a new European CE mark approval for mixing with antibiotics: vancomycin, gentamicin and tobramycin, for use in infected bone and soft tissue. 
 
STIMULAN targets high concentrations of antibiotic at the point of infection at levels unachievable systemically—which lowers rates of reinfection, saves costs and improves patient outcomes. The STIMULAN Rapid Cure and STIMULAN Kit products are the first and only calcium matrices that can carry an antibiotic into bone and soft tissue; offering surgeons the flexibility to apply a broad spectrum of ‘off-the-shelf’ antibiotics at concentrations that will support their patient-specific treatment plans.
 
Rhidian Morgan-Jones, Consultant Orthopedic Surgeon, said: “STIMULAN is the only product that allows me to place the appropriate antibiotics in bone and soft tissue when treating very challenging infected cases. It has played a key role in transforming the outcomes of some very difficult cases.”
 
Michael Harris, CEO of Biocomposites, said: “Our goal is to develop and provide products that can significantly improve patient outcomes and decrease hospital readmissions. This is a breakthrough solution for surgeons managing infection, offering them the flexibility to use their chosen antibiotics at patient-specific concentration levels in both bone and soft tissue.”

STIMULAN is already used in over 50,000 cases every year and in thousands of hospitals around the world.